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Abstract Resumen 
Context: Naringin (NRG) is the major flavonoid (flavanone glycoside) in 
grapefruit juice. Its biological activity has been only partially 
characterized and little is known about the mechanism of the negative 
inotropic action of this flavonoid.  
Aims: To evaluate the effects of NRG on the surface electrogram (ECG) 
and the force of contraction (FC) of mice hearts as well as on the sodium 
(INa), calcium (ICaL) and Na
+ - Ca2+ exchange (INaCaX) currents of 
enzymatically isolated mouse ventricular cardiomyocytes.  
Methods: ECG and FC were recorded on mouse hearts perfused in a 
Langendorff column. Ventricular cardiomyocytes were enzimatically 
dissociated and ionic currents recorded with the patch-clamp technique.  
Results: NRG increased RR interval and shortened corrected QT only at 
high concentrations (30-100 µM). However, at a fixed heart rate, it 
decreased FC with an IC50 of 0.4 µM. NRG reduced INa with an IC50 of 0.07 
µM but with a maximal inhibition of 60 %. NRG also depressed ICaL with 
an IC50 of 0.013 µM and increased its fast inactivation time constant. The 
effects on ICaL were not voltage-dependent. INaCaX was not affected by 
NRG.  
Conclusions: Our results indicate that NRG exerts a negative inotropic 
effect in mice hearts that could be explained by a decrease in INa and ICaL. 
These actions should be taken into account when considering this 
molecule either as a dietetic supplement or as a template to develop 
therapeutic agents for human diseases.  
Contexto: La naringina (NRG) es el principal flavonoide (glicósido de 
flavanona) en el jugo de toronja. Su actividad biológica ha sido solo 
parcialmente caracterizada y poco se conoce acerca del mecanismo de la 
acción inotrópica negativa de este flavonoide.  
Objetivos: Evaluar los efectos de la NRG sobre el electrograma de 
superficie (ECG) y la fuerza de contracción (FC) de corazones de ratón, así 
como sobre las corrientes de sodio (INa), calcio (ICaL) y del intercambiador 
Na+ - Ca2+ (INaCaX) en cardiomiocitos ventriculares de ratón, aislados 
enzimáticamente.  
Métodos: El ECG y la FC se registraron en corazones de ratón 
perfundidos en una columna de Langendorff. Los cardiomiocitos 
ventriculares se disociaron enzimáticamente y las corrientes iónicas se 
registraron con la técnica de patch-clamp.  
Resultados: La NRG incrementó el intervalo RR intervalo y acortó el QT 
solo a altas concentraciones (30-100 µM). No obstante, a frecuencia 
cardíaca fija, disminuyó la FC con un IC50 de 0.4 µM. La NRG redujo INa 
con un IC50 de 0.07 µM pero con una máxima inhibición de 60 %. La NRG 
también redujo ICaL con un IC50 de 0.013 µM e incrementó su constante de 
inactivación rápida. Los efectos sobre ICaL no fueron dependientes del 
potencial. La INaCaX no fue afectada por la NRG.  
Conclusiones: Nuestros resultados indican que la NRG ejerce un efecto 
inotrópico negativo en corazones de ratón que puede ser explicado por 
una reducción en INa e ICaL. Esas acciones deben ser tomadas en cuenta al 
considerar a esta molécula como suplemento dietético o como plantilla 
para desarrollar nuevos agentes terapéuticos para tratar las enfermedades 
en humanos.  
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INTRODUCTION 
There is evidence for an association between 
high dietary intake of flavonoids and a reduction 
of myocardial infarction and stroke (Hertog et al., 
2012; Keli et al., 1996). It is widely accepted that these 
natural compounds could have a potential thera-
peutic value in the prevention and treatment of 
cardiovascular diseases (Benavente-García and Castillo, 
2008; Habauzit and Morand, 2012) due to their anti-
oxidant, anti-inflammatory, anti-proliferative and 
anti-thrombotic actions (see for reviews Bharti et al., 
2014; Wright et al., 2013). However, the intracellular 
modulator actions of flavonoids are diverse and 
complex (Wright et al., 2013) and can be affected by 
sex, lifestyle, disease states and interactions with 
drugs thus limiting their impact on human health 
(Wright et al., 2013; Chanet et al., 2012). Nonetheless, 
these compounds are extremely interesting as 
molecular templates to design drugs with better 
pharmacological profiles for the treatment of 
human cardiovascular diseases. 
The flavanone naringin is the major flavonoid 
in grapefruit juice, an important dietary source of 
flavonoids, and gives the grapefruit juice its bitter 
taste (Peterson et al., 2006). When it is ingested, NRG 
is transformed and converted to several meta-
bolites (including naringenin) in blood and urine. 
However, naringin (and naringenin) could be 
detected in plasma around 5 hours after oral 
administration (Bharti et al., 2014; Fuhr and Kummert, 
1995). Naringin seems to have a cardioprotective 
action in isoproterenol-induced myocardial 
infarction in rats (Rajadurai and Prince, 2007). In 
stroke-prone spontaneously hypertensive rats, 
orally-administered naringin was reported to 
suppress the age-related increase in blood 
pressure, to significantly decrease thrombotic 
tendency and to increase nitric oxide (NO) pro-
duction thus improving endothelium-dependent 
vasodilation (Ikemura et al., 2012). Nevertheless, part 
of these effects could be also probably due to the 
actions of naringenin, the aglycone formed du-
ring the cleavage of the sugar moiety of naringin 
after its ingestion (Fuhr and Kummert, 1995). Naringe-
nin, by activating mitochondrial BK potassium 
channels could protect against ischemia-
reperfusion injury (Testai et al., 2013). However, 
there is still the need of investigations about the 
possible direct cardiovascular physiological ac-
tions of naringin. Saponara et al. (2006) showed 
that naringin could increase the conductance of 
vascular smooth muscle calcium-activated pota-
ssium ion channels (BK(Ca)) but exhibited a poor 
vasorelaxing action in rat aortic rings compared 
to its aglycone naringenin. Recently, Saponara et 
al. (2011) described that a number of flavonoids 
stimulated or inhibited ICaL in rat tail artery 
myocytes. They found that naringin and 
naringenin modestly inhibited ICaL. We have 
previously reported that naringin, at pharmacolo-
gical relevant concentrations, induced contrac-
tion of rat aortic rings and exerted a modest 
negative inotropic effect on isolated rat hearts 
(López-Medina et al., 2014). Since naringin could be 
used as a dietary supplement, antioxidant, 
antiinflammatory and even as a template to 
develop cardiovascular drugs, it is important to 
investigate its actions on the voltage-dependent 
Na+ and Ca2+ channels and on the current 
generated by the Na+ - Ca2+ exchanger in an 
attempt to elucidate the mechanism of the 
negative inotropic action of this flavonoid.  
MATERIALS AND METHODS 
Chemicals 
Naringin (4’,5,7-trihydroxyflavanone 7-rham-
noglucoside; C27H32O14, PubChem CID: 25075; 
>95% HPLC), nifedipine (1,4-dihydro-2,6-dime-
thyl-4-(2-nitrophenyl)-3,5-pyridinedicarbo-xylic 
acid dimethyl ester; C17H18N2O6; PubChem CID: 
4485; >98% HPLC) and lidocaine (2-diethylami-
no-N-(2,6-dimethylphenyl)acetamide; C14H22N2O; 
PubChem CID: 3676; 99.9% HPLC) were purcha-
sed from Sigma Aldrich and were prepared in 
ethanol as 0.1 M (naringin and lidocaine) and 10 
µM (nifedipine) stock solutions. All other 
chemicals were also from Sigma Aldrich.  
Animals 
Experiments were performed using male adult 
C57BL/6 (7-8 weeks) mice according to the 
procedures approved by the Centro Nacional para 
la Producción de Animales de Laboratorio 
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(CENPALAB, Santiago de Las Vegas, Habana, 
Cuba). Prior to experiment animals were adapted 
for seven days to laboratory conditions (contro-
lled temperature 25 ± 2°C, relative humidity 60 ± 
10% and 12 h light/dark cycles). Tap water and 
standard diet for rodents supplied by CENPALAB 
were freely provided. All procedures were also 
conducted according to the European Commis-
sion guide-lines for the use and care of laboratory 
animals and approved by the Committee for 
Animal Care in Research of the Center. The 
minimum number of animals and duration of 
observation required to obtain consistent data 
were employed. 
Recording of electrical and mechanical 
activities in isolated hearts 
Mouse hearts were carefully dissected and 
mounted on a Langendorff column to record the 
surface electrogram (ECG) and the force of 
contraction (FC) as previously described (Galán et 
al., 1998). ECG and FC values were recorded at the 
spontaneous heart rate and at a fixed stimulus 
rate (200 bpm). 
Enzymatic isolation of ventricular cardio-
myocytes 
Ventricular cardiomyocytes were isolated as 
previously described (Alvarez-Collazo et al., 2012) and 
were kept in a K+-Tyrode solution containing 1 
mM Ca2+ at room temperature (21 ± 2 °C) and 
used for experiments for 6 h.  
Patch-clamp recordings 
Whole-cell currents were recorded at room 
temperature (Alvarez-Collazo et al., 2012). Currents 
were filtered at 3 kHz and digitized at 50-μs 
intervals, stored on a computer and analysed off-
line with the ACQUIS1 software (version 2.0, 
CNRS License, France). To study Na+ and Ca2+ 
currents, K+ currents were blocked by substitu-
ting all potassium by cesium in extracellular and 
“intracellular” solutions. The extracellular solu-
tion contained (in millimolars): 117 NaCl, 20 CsCl, 
10 HEPES, 2 CaCl2, 1.8 MgCl2, and 10 glucose, pH 
7.4. The standard pipette (intracellular) solution 
contained (in millimolars): 130 CsCl, 0.4 Na2GTP, 
5 Na2ATP, Na2-creatine phosphate, 2.0 MgCl2, 11 
EGTA, 4.7 CaCl2 (free Ca
2+, 108 nM), and 10 
HEPES, with pH adjusted to 7.2 with CsOH. 
Pipette resistance was 1.0-1.2 MΩ. Membrane 
capacitance (Cm) and series resistance (Rs) were 
calculated on voltage-clamped cardiomyocytes as 
previously described (Alvarez et al., 2000). Average 
Cm and uncompensated Rs were 170 ± 10 pF and 
3.7 ± 0.3 MΩ, respectively (N = 63). Rs could be 
electronically compensated up to 50% without 
ringing and was continually monitored during 
the experiment. Liquid junction potential was 
compensated before establishing the gigaseal. No 
leak or capacitance subtractions were performed 
in the recordings. 
The fast Na+ current (INa) was evoked with 50-
ms voltage-clamp pulses to -40 mV, applied from 
a holding potential (HP) of -100 mV (1/4 s). In an 
attempt to decrease the huge INa and improve 
voltage control during patch-clamping, the extra-
cellular Na+ concentration was reduced to 10 mM 
keeping osmolarity with (107 mM) tetraethyl-
ammonium chloride. Nifedipine (10 µM) was 
used in these experiments to block the L-type 
Ca2+ current (ICaL). For routine monitoring of ICaL 
a double pulse voltage-clamp protocol was 
employed: from a holding potential (HP) of -80 
mV every 4s the cell membrane was depolarized 
to -40 mV for 50 ms to inactivate the fast Na+ 
current. From this membrane potential a 300-ms 
pulse to +10 mV evoked ICaL. The inactivation 
time courses of INa and ICaL were fitted to a single 
(INa) or a double exponential (ICaL) using the 
fitting procedures of the ACQUIS1 software. 
In other experiments the Na+/Ca2+ exchange 
current (INaCaX) was estimated by using 500-ms 
ramp voltage clamps from +70 to -100 mV (1/15 s; 
HP = -40 mV). In those experiments nifedipine 
(10 µM), ouabain (10 µM) and NiCl2 (5 mM) were 
used to block ICaL, the Na
+-K+ pump and INaCaX, 
respectively. 
Statistical analysis  
Results are expressed as means and standard 
errors of means. Statistical significance was eva-
luated by means of paired or unpaired Student’s t 
test according to the experimental situation. 
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Differences were considered statistically signify-
cant for p < 0.05. 
RESULTS 
Effects of NRG on electrical and mechanical 
activities in isolated hearts  
In six hearts, a wide range of NRG 
concentrations (0.001 - 100 µM) exerted variable 
effects on the QRS in such a way that, although 
there was a tendency to increase its duration and 
decrease its amplitude, no statistically significant 
effects could be demonstrated. RR interval was 
only significantly increased by NRG from 208 ± 2 
ms in control to 235 ± 8 ms and 514 ± 17 ms at 30 
and 100 µM concentrations respectively (p < 
0.05). Corrected QT (QTc = QT/√RR) was not 
significantly affected by low NRG concentrations 
(up to 10 µM). However, at 30 and 100 µM con-
centrations, NRG decreased QTc (from 13 ± 1 ms 
in control to 8 ± 1.5 ms and 6.5 ± 2 ms, respec-
tively; p < 0.05). On the other hand, NRG (0.001 - 
100 μM) significantly decreased the FC in isolated 
hearts. Hearts were paced at 200-ms stimulus 
interval (slightly over the spontaneous RR 
interval under control condition; 208 ± 2 ms) in 
order to avoid any frequency-dependent changes 
in FC. Experimental data were fitted to a Hill 
function and the estimated IC50 for inhibition of 
contraction was 0.4 ± 0.1 µM (Hill number = 0.6 ± 
0.08), comparable to that of nifedipine (IC50 = 0.3 
± 0.05 µM; Hill number = 1.5 ± 0.04; n = 5). The 
action of NRG on FC was reversible upon 
washout with normal Tyrode solution. 
Effects of NRG on sodium current 
In control condition (10 mM extracellular Na+) 
peak inward INa at -40 mV was 14.5 ± 2.2 pA/pF (N 
= 28). Its inactivation time course could be fitted 
to a single exponential with a time constant of 2.2 
± 0.2 ms. Concentrations of NRG as low as 0.02 
µM decreased INa by ~ 40 %. The decrease in INa 
was not use-dependent and occurred in an 
almost “on-off” fashion (Fig. 1A). Increasing NRG 
concentration barely increased INa block. The 
experimental data were fitted to a Hill function 
and the estimated IC50 for INa (at -40 mV) inhibi-
tion by NRG was 0.07 ± 0.01 µM with a Hill 
number of 0.83 ± 0.07 but with a maximal INa 
inhibition of only 60.1 ± 1.1 % (Fig. 1B). In sharp 
contrast, the reference compound lidocaine (a 
classic local anesthetic; 1 - 300 µM), inhibited INa 
in a typical use-dependent fashion with an IC50 of 
23.5 ± 3.1 µM (Hill number, 0.9 ± 0.08) but with a 
maximal inhibition of 96.3 ± 3.9% (Fig. 1B). The 
decrease of INa by NRG was accompanied by 
variable changes in its inactivation time course. 
The inactivation time constant of INa was signify-
cantly increased only at concentrations higher 
than 0.02 µM (Fig. 2). The effects of different 
lidocaine concentrations on the inactivation time 
constant of INa were not statistically significant. 
As noted above, we used a 10 mM Na+ extra-
cellular solution in an attempt to minimize 
voltage-clamp errors during the flow of a large 
INa. However, even under this condition the re-
corded Na+ current density was large and, due to 
the presence of a residual series resistance (~ 2 
MΩ after compensation), the estimated error 
factor during the flow of INa could be large (see 
Alvarez et al., 2000). This precluded a detailed ana-
lysis of INa kinetics in all studied cells. In cells 
where the error factor was small (< 4 mV), we 
studied the effects of 0.06 µM NRG (a concen-
tration near the IC50) on I-V, availability and acti-
vation curves of INa. Cardiomyocytes were clam-
ped at a HP of -100 mV and a double-pulse volta-
ge-clamp protocol was applied at a frequency of 
0.125 Hz. A fixed 50-ms test pulse to -40 mV was 
preceded by 50-ms prepulses applied from -50 to 
+50 mV. A short 2-ms gap at the HP separated 
pre- and test pulses. To obtain the availability 
curve, INa at each test pulse was normalized to 
maximal INa and plotted against the prepulse 
potential. Activation curve was obtained by 
calculating the chord conductance at each test 
potential and normalizing by the maximal chord 
conductance. Experimental data of availability 
and activation curves were fitted to Boltzmann 
functions to obtain mid points for activation and 
availability (V0.5) and the slope factors (s). As can 
be seen in Fig. 3 (A-C) the action of NRG seemed 
to be almost voltage-independent. Potentials for 
half inactivation and activation (V0.5) were barely 
shifted from -73.6 ± 0.3 mV (slope factor, s = 7.4 ± 
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0.3 mV) to -75.6 ± 0.2 mV (s = 7.1 ± 0.2 mV) and 
from -37.2 ± 0.4 mV (s = 5.1 ± 0.2 mV) to -36.7 ± 
0.5 mV (s = 4.7 ± 0.1 mV), respectively (n = 4). On 
the other hand, lidocaine (30 µM; near the IC50), 
had a typical voltage-dependent action and 
shifted the V0.5 for inactivation from -77.3 ± 1.1 
mV (s = 7.6 ± 0.4 mV) to -86.5 ± 1.0 mV (s = 7.1 ± 
0.2 mV) and the V0.5 for activation from -38.8 ± 1.2 
mV (s = 5.7 ± 0.3 mV) to -33.8 ± 1.1 mV (s = 5.6 ± 
0.5 mV; p < 0.05; n = 5). 
 
 
 
Figure 1. Effects of NRG on the Na
+
 current in mouse 
ventricular cardiomyocytes. A: Example of the effects of 
extracellular application of NRG at two concentrations (0.02 
– 0.06 µM) on INa recorded at -40 mV. The insets show the 
current traces corresponding to the time points indicated by 
the labels. B: Concentration-response curves for the inhi-
bition of INa by NRG and lidocaine. Experimental data (n ≥ 4 
for each point) were fitted to a Hill function. 
 
Figure 2. Concentration-dependent effects of NRG on the 
inactivation time course of INa. Inactivation time course of 
INa could be fitted to one exponential. Although with some 
variability, the inactivation time constant of INa was incre-
ased by NRG at concentrations of 0.02 µM or greater. The 
asterisks denote statistically significant effects of NRG (p < 
0.05) with respect to the value obtained in control condition 
(arrow). 
 
 
Figure 3. Effects of NRG on the voltage dependence of 
activation and inactivation of Na
+
 current in mouse ven-
tricular cardiomyocytes. A: Representative current traces 
recorded at -40 mV (HP = -100 mV) in control and in the 
presence of NRG 0.06 µM (a concentration near the IC50). B: 
Effect of NRG (0.06 µM) on the current-voltage (I-V) 
relationship of INa. Note that NRG produced no shift on the 
I-V curve. C: Availability and activation curves of INa 
obtained in control and in the presence of 0.06 µM NRG. 
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Effects of NRG on the L-type calcium current 
In control condition mean ICaL density at +10 
mV was 6.2 ± 0.3 pA/pF (N = 25). Its inactivation 
time course was fitted to two exponentials yiel-
ding 6.3 ± 0.3 ms and 51.6 ± 2.2 ms for fast (τfast) 
and slow (τslow) components, respectively. Perfu-
sion of cardiomyocytes with NRG resulted in a 
pulse to pulse decrease of ICaL that reached a 
steady state in ~ 30 s (Fig. 4A). The effects of NRG 
were concentration-dependent and were charac-
terized by an IC50 of 0.013 ± 0.001 µM, a Hill 
number (N) of 0.6 ± 0.02 and a maximal inhibi-
tion (Bmax) of 100%. This IC50 is about one order 
of magnitude lower than that of nifedipine (0.1 ± 
0.07 µM, N = 0.9 ± 0.05, Bmax = 100%; n ≥ 5 cells 
for each concentration). NRG slowed down ICaL 
inactivation. This effect was characterized by a 
small but significant increase of τfast at low 
concentrations and a huge increase at 2 and 6 µM 
concentrations (Fig. 4B). Although τslow showed a 
tendency to be increased in the presence of 
different NRG concentrations, changes were not 
statistically significant. The relationships of τfast 
and τslow with membrane voltage were “U” shaped 
with a minimum between 0 and +10 mV. The 
clear-cut increase in τfast by NRG was not voltage-
dependent as proportionate increases were 
observed for all imposed membrane potentials at 
the studied concentrations (data not shown). 
To study the effects of NRG on ICaL kinetics 
cardiomyocytes were clamped at a HP of −80 mV 
and a double-pulse voltage-clamp protocol was 
applied at a frequency of 0.125 Hz. A fixed 300-ms 
test pulse to +10 mV was preceded by 300-ms 
prepulses applied from -50 to +70 mV. A short 5-
ms gap at the HP separated pre- and test pulses. 
To obtain the availability curve, ICaL at each test 
pulse was normalized to maximal ICaL and plotted 
against the prepulse potential. Activation curve 
was obtained by calculating the chord conduc-
tance at each test potential and normalizing by 
the maximal chord conductance. 
Experimental data of availability and activa-
tion curves were fitted to Boltzmann functions to 
obtain mid points for activation and availability 
(V0.5) and the slope factors (s). The action of NRG 
on ICaL was barely voltage-dependent (Fig. 5A). At 
0.02 µM concentration (near the IC50) NRG shif-
ted the V0.5 of ICaL inactivation from -28.0 ± 1.7 
mV to -30.04 ± 0.4 mV (not significant; n = 5). ICaL 
activation was also scarcely affected, V0.5 was 
shifted from -16.6 ± 0.2 mV to -13.6 ± 0.3 mV (not 
significant; Fig. 5B). 
 
 
 
Figure 4. Effects of NRG on the L-type Ca
2+
 current in 
mouse ventricular cardiomyocytes. A: Example of the effects 
of extracellular application of NRG at concentrations of 0.02 
and 0.2 μM on ICaL recorded at +10 mV. The insets show the 
current traces corresponding to the time points indicated by 
the labels. I-V labels indicate periods at which current-to-
voltage relationships were constructed. B: Concentration-
dependent effects of NRG on the time constants of fast (τfast) 
and slow (τslow) inactivation of ICaL evoked at +10 mV. The 
asterisks denote statistically significant effects of NRG (p < 
0.05) with respect to τfast and τslow obtained in control 
condition (arrows). 
 
Higher concentrations of NRG resulted in 
similar changes in V0.5 of both activation and 
availability. No significant changes were observed 
in the corresponding slope factors or on the ICaL 
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availability at positive prepulse potentials. The 
reference compound nifedipine exhibited a 
marked voltage-dependent action with significant 
(p < 0.05; n = 5) shifts in V0.5 for availability and 
activation from -27.1 ± 2.0 mV to -38.2 ± 0.5 mV 
and from -17.2 ± 0.3 mV to -12.5 ± 0.4 mV, 
respectively. The corresponding slope factors 
were 6.9 ± 0.5 mV and 6.5 ± 0.4 mV for availa-
bility and 6.3 ± 0.2 mV and 6.5 ± 0.3 mV for 
activation. 
 
 
Figure 5. Effects of NRG on the voltage dependence of acti-
vation and inactivation of L-type Ca
2+
 current in mouse ven-
tricular cardiomyocytes. A: Effect of NRG, at a concentration 
near the IC50 on the current-voltage (I-V) relationship of ICaL. 
Note that NRG produced no shift on the I-V curve. The inset 
shows representative current traces recorded in control and 
in the presence of 0.02 μM NRG. B: Availability and activa-
tion curves of ICaL obtained in control and in the presence of 
0.02 µM NRG. 
Lack of effect of NRG on the Na+ - Ca2+ 
exchange current 
Taking advantage of the voltage-dependency of 
the Na+ - Ca2+ exchanger (Bers, 2001), we used 500-
ms ramp voltage clamps from +70 to -100 mV 
from an HP of -40 mV in an experimental 
condition where ICaL and the Na
+-K+ pump were 
blocked. INaCaX was estimated using NiCl2 (5 mM) 
a known blocker of the Na+ - Ca2+ exchanger. In 
six cardiomyocytes, NRG at high concentration 
(30 µM) had no effect on the Ni2+ sensitive 
current. Under control condition INaCaX densities 
at +60 (I+60) and -90 mV (I-90) were 1.22 ± 0.12 
pA/pF and -0.91 ± 0.7 pA/pF, respectively. The 
reversal potential was -15.3 ± 1.2 mV. In the 
presence of NRG I+60 and I-90 were 1.17 ± 0.11 and -
0.96 ± 0.09 pA/pF, respectively and the reversal 
potential was -15.1 ± 1.1 mV. 
DISCUSSION  
The present results show that NRG possesses 
“Ca2+-antagonist” properties. This flavanone 
glycoside exerts a negative inotropic action in 
mouse heart and decreased both Na+ and Ca2+ 
currents. We thus confirm that NRG exerts a 
negative inotropic action on rodent hearts (c.f. 
López-Medina et al., 2014). However, to our surprise, 
in mouse heart, NRG was as potent as the 
classical Ca2+-antagonist nifedipine. As shown in 
Results, the concentration-dependent negative 
inotropic action of NRG was accompanied by 
minor changes in electrical activity at concen-
trations around the IC50 for the inhibition of con-
tractile force. Physiologically significant shorte-
ning of QTc and an increase in RR interval were 
seen only at high concentrations well over the 
effective plasma concentrations found by Xiao-
Hong et al. (2010). It should be considered that 
NRG could exert multiple actions on different 
ionic channels that balance to each other, resul-
ting in scarce effects on the cardiac surface 
electrogram. The negative inotropic effect of NRG 
was more evident and this prompted us to study 
the effects of NRG on three major protagonists of 
cardiac contraction, the fast Na+ current, the L-
type Ca2+ current and the Na+ - Ca2+ exchange 
current. 
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NRG decreased INa in a concentration-
dependent manner with an IC50 (0.07 µM) much 
smaller than that of the classic local anesthetic 
lidocaine (see also Tan and Saint, 2000) but with a 
lower potency since maximal block achieved was 
~ 60%. Further experiments are needed to under-
stand this specific feature of NRG action on Na+ 
current (potent but incomplete inhibition). As 
discussed above, INa was recorded in a Na
+-poor 
extracellular solution. We cannot rule out that 
the IC50 for NRG inhibition of INa could be diffe-
rent at physiological extracellular Na+ concentra-
tions. It has been reported for Na+ channels that 
the permeant ion might influence channel block 
by antiarrhythmic drugs by the so-called “knock 
out” effect (Barber et al., 1992). NRG block of INa was 
not use-dependent; channel block occurred in an 
almost “on-off” fashion and was not voltage-
dependent (activation and availability curves 
were barely modified). Although not explored in 
detail, the results suggest that NRG blocks Na+ 
channels in the open state. Due to the lack of 
voltage dependency, it can be assumed that NRG 
blockade of Na+ channel could take place by 
simply plugging the channel and not by interfe-
ring with channel gating process but this requires 
further investigation. In any case, blockade of INa 
could decrease Na+ load and have some effect in 
cardiac contraction (Bers, 2001). However, it is 
evident that most of the negative inotropic effect 
of NRG could be due to its blocking action on 
ICaL. 
Blockade of ICaL by NRG was concentration-
dependent and was achieved in a pulse-to-pulse 
manner, an action that is reminiscent of that of 
the classic phenylalkylamine Ca2+ channel blocker 
verapamil (Rubio et al., 1993). NRG blocked ICaL with 
an IC50 of 0.013 µM, about one order of magnitude 
lower than that of nifedipine (0.1 µM) but unlike 
nifedipine's classic action, blockade of ICaL by 
NRG was poorly voltage-dependent with only 
minor changes in availability and activation 
curves. The inhibition of ICaL was accompanied by 
an increase in fast inactivation time constant τfast 
with maximal increases at 2-6 μM concentrations 
for maximal ICaL evoked at +10 mV. Although τslow 
showed a tendency to increase in the presence of 
different NRG concentrations, changes were not 
statistically significant. Our results confirm in 
part those of Saponara et al. (2011) who showed 
that naringin and its aglycone naringenin modes-
tly inhibited ICaL in rat tail artery myocytes. 
However, besides that cell type and experimental 
conditions were different, it is difficult to explain 
why NRG was more potent on ICaL in mouse 
ventricular cardiomyocytes than in rat arterial 
smooth muscle cells. As Saponara et al. (2011) 
suggested, the flavonoid scaffold could be a 
valuable template for the design of novel drugs 
acting on vascular smooth muscle Cav1.2 chan-
nels for the treatment of hypertension and stroke. 
On the other hand, in experiments on recom-
binant human KIR3.1-3.4 and KIR3.1-3.2 expressed 
in Xenopus oocytes or HAC15 cells (Oki et al., 2012; 
Yow et al., 2011), naringin (but not naringenin) was 
shown to be a direct activator of inward rectifying 
K+ currents, an effect that, together with its 
action on ICaL, could have an impact on heart rate 
at least in isolated heart or spontaneous activity 
in single cell preparations. Since we found no 
evidence of a NRG action on INaCaX, the inhibition 
of L-type Ca2+ channels in mouse ventricular car-
diomyocytes can easily explain the negative 
inotropic effect we found in isolated mouse 
hearts. However, we cannot rule out effects of 
NRG on other systems (e.g. ryanodine receptor, 
Ca2+-ATPase) that could also affect contractile 
force. 
NRG is an important active ingredient in 
citrus fruits, a major source of dietetic flavonoids. 
As stated before, there is an interest on flavo-
noids (and NRG) not only as dietetic supplements 
but also as templates to develop therapeutic 
agents for the treatment of several human disea-
ses. Besides its cardiovascular effects described 
here, it has been reported that NRG possesses 
antioxidant and neuroprotective (Choi et al., 2010) 
actions. It also acts as an anti-inflammatory (Jain 
and Parmar, 2011). NRG is reported to be able to 
decrease total cholesterol levels (Lee et al., 2001) and 
to inhibit high glucose-induced apoptosis by 
attenuating mitochondrial dysfunction (Huang et 
al., 2013). It is thus important to study its pharma-
cological properties in order to identify the 
beneficial profile and as well its undesirable 
effects (Bharti et al., 2014). Here we show that NRG 
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could have a negative inotropic action in heart 
due to a blocking action on Na+ and Ca2+ chan-
nels. Whether these effects are relevant or not to 
human health require further investigation. 
CONCLUSIONS 
We may conclude that NRG exerts a negative 
inotropic effect in mouse heart. This effect could 
be explained by its inhibitory action on sodium 
and calcium currents. These actions should be 
taken into account when considering this mole-
cule either as a dietetic supplement or as a 
template to develop therapeutic agents for 
human diseases.  
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